128 related articles for article (PubMed ID: 36483043)
1. Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.
Zhao J; Chi Y; Hu C; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Li D; Tang P; Gao M; Zheng X
Front Oncol; 2022; 12():852032. PubMed ID: 36483043
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhong Q; Liu Z
Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
[TBL] [Abstract][Full Text] [Related]
4. Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703).
Chi Y; Shu Y; Ba Y; Bai Y; Qin B; Wang X; Xiong J; Xu N; Zhang H; Zhou J; Xu J; Cheng Y; Feng J; Hu C; Chen Y; Chen Z; Wang J; Dang C; Wang J; Wan Y; Tang Y; Wang D; Liu J; Wu M; Deng Y; Li X; Li Y; Dong J; Jiang D; Li G; Wu Q; Li J; Qi Y; Sun Y; Cai J
Oncologist; 2021 Oct; 26(10):e1693-e1703. PubMed ID: 34105207
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.
Chi Y; Zheng X; Zhang Y; Shi F; Cheng Y; Guo Z; Ge M; Qin J; Zhang J; Li Z; Zhou X; Huang R; Chen X; Liu H; Cheng R; Xu Z; Li D; Tang P; Gao M
Clin Cancer Res; 2023 Oct; 29(20):4047-4056. PubMed ID: 37594724
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
7. Third-line or above anlotinib in relapsed and refractory small cell lung cancer patients with brain metastases: A post hoc analysis of ALTER1202, a randomized, double-blind phase 2 study.
Cheng Y; Wang Q; Li K; Shi J; Han B; Wu L; Chen G; He J; Wang J; Qin H; Li X
Cancer Innov; 2023 Jun; 2(3):181-190. PubMed ID: 38089404
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract][Full Text] [Related]
9. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Zhao Y; Yu H; Zhao Y; Chen W; Luo Y; Wu L; Wang X; Pirker R; Nan K; Jin F; Dong J; Li B; Sun Y
JAMA Oncol; 2018 Nov; 4(11):1569-1575. PubMed ID: 30098152
[TBL] [Abstract][Full Text] [Related]
10. Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial.
Cheng Y; Han B; Li K; Wang Q; Zhang L; Shi J; Wang Z; He J; Shi Y; Chen W; Wang X; Luo Y; Nan K; Jin F; Li B; Zhu J
Cancer Med; 2020 Apr; 9(8):2621-2630. PubMed ID: 32064794
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial.
Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Cancer Med; 2022 Feb; 11(4):1081-1087. PubMed ID: 34939373
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study.
Zhao Y; Wang Q; Zhang L; Shi J; Wang Z; Cheng Y; He J; Shi Y; Chen W; Luo Y; Wu L; Wang X; Nan K; Jin F; Dong J; Li B; Yamaguchi F; Breadner D; Nagano T; Tanaka F; Husain H; Li K; Han B
Transl Lung Cancer Res; 2022 May; 11(5):776-785. PubMed ID: 35693290
[TBL] [Abstract][Full Text] [Related]
13. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.
Liu Y; Cheng Y; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X; Hamaji M; Park HS
Transl Lung Cancer Res; 2021 Sep; 10(9):3793-3806. PubMed ID: 34733629
[TBL] [Abstract][Full Text] [Related]
14. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
Han B; Li K; Zhao Y; Li B; Cheng Y; Zhou J; Lu Y; Shi Y; Wang Z; Jiang L; Luo Y; Zhang Y; Huang C; Li Q; Wu G
Br J Cancer; 2018 Mar; 118(5):654-661. PubMed ID: 29438373
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Anlotinib on Brain Metastases of Non-Small Cell Lung Cancer: Post Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303).
Jiang S; Liang H; Liu Z; Zhao S; Liu J; Xie Z; Wang W; Zhang Y; Han B; He J; Liang W
Oncologist; 2020 May; 25(5):e870-e874. PubMed ID: 32077550
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib Combined with Cranial Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastasis: A Retrospectively, Control Study.
He Z; Liu J; Ma Y; Jiang H; Cui Z; Wang G; Wu Y; Liu J; Cai X; Qian J; Huang J; Zhang H; Li H
Cancer Manag Res; 2021; 13():6101-6111. PubMed ID: 34377028
[TBL] [Abstract][Full Text] [Related]
17. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study.
Zhang S; Wang X; Gu H; Liu JQ
Cancer Manag Res; 2022; 14():1715-1727. PubMed ID: 35592110
[TBL] [Abstract][Full Text] [Related]
19. Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study.
Nan X; Xie C; Zhu Q; Zhang J; Fu S; Han X; Zhang Q; Han B; Liu J
Int J Clin Oncol; 2020 Aug; 25(8):1492-1498. PubMed ID: 32447474
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]